Role of omega-3 ethyl ester concentrate in reducing sudden cardiac death following myocardial infarction and in management of hypertriglyceridemia: an Indian consensus statement.

Autor:	Dalal JJ; Kokilaben Dhirubhai Ambani Hospital, Mumbai, India. jjdalal@hotmail.com, Kasliwal RR, Dutta AL, Sawhney JP, Iyengar SS, Dani S, Desai N, Sathyamurthy I, Rao D, Menon A, Dasbiswas A, Wander GS, Chadha M, Hiremath MS, Roy DG, Gupta V, Shivakadaksham N
Jazyk:	angličtina
Zdroj:	Indian heart journal [Indian Heart J] 2012 Sep-Oct; Vol. 64 (5), pp. 503-7. Date of Electronic Publication: 2012 Aug 27.
DOI:	10.1016/j.ihj.2012.08.004
Abstrakt:	Introduction: Sudden cardiac death (SCD) is the most lethal manifestation of heart disease. In an Indian study the SCDs contribute about 10% of the total mortality and SCD post ST elevation myocardial infarction (MI) constitutes for about half of total deaths. Objective: Given the limitations of existing therapy there is a need for an effective, easy to use, broadly applicable and affordable intervention to prevent SCD post MI. Leading cardiologists from all over India came together to discuss the potential role of n-3 acid ethyl esters (90%) of eicosapentaenoic acid (EPA) 460 mg & docosahexaenoic acid (DHA) 380 mg in the management of post MI patients and those with hypertriglyceridemia. Recommendations: Highly purified & concentrated omega-3 ethyl esters (90%) of EPA (460 mg) & DHA (380 mg) has clinically proven benefits in improving post MI outcomes (significant 15% risk reduction for all-cause mortality, 20% risk reduction for CVD and 45% risk reduction in SCD in GISSI-Prevenzione trial) and in reducing hypertriglyceridemia, and hence, represent an interesting option adding to the treatment armamentarium in the secondary prevention after MI based on its anti-arrhythmogenic effects and also in reducing hypertriglyceridemia. (Copyright © 2012 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu